<DOC>
	<DOCNO>NCT00903331</DOCNO>
	<brief_summary>The AC-055B201/MUSIC study Phase II study , compare one dose ACT-064922 ( macitentan ) 10 mg placebo patient idiopathic pulmonary fibrosis ( IPF ) . The main study objective demonstrate macitentan positively affect forced vital capacity ( FVC ) comparison placebo patient idiopathic pulmonary fibrosis ( IPF ) . The secondary objective evaluate effect macitentan time disease worsen death patient IPF , evaluate benefit/risk profile macitentan treatment patient IPF .</brief_summary>
	<brief_title>Macitentan Use Idiopathic Pulmonary Fibrosis Clinical Study</brief_title>
	<detailed_description>The study include two treatment period : Period 1 ( fix duration ) randomization primary endpoint evaluation ( Month 12 early case premature discontinuation study drug ) Period 2 ( variable duration ) primary endpoint evaluation visit end study ( EOS ) . EOS occur last patient randomize prematurely discontinue complete Period 1 .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent . 2 . Male female patient least 18 year age ( female childbearing potential must use reliable method contraception ) . 3 . IPF diagnosis within 3 year prior randomization , proven accord American Thoracic Society/European Respiratory Society consensus conference criterion , surgical lung biopsy . 1 . Interstitial lung disease due condition IPF . 2 . Presence extensive honeycombing Baseline highresolution compute tomography ( HRCT ) scan perform within 3 month prior randomization . 3 . Severe concomitant illness limit life expectancy ( &lt; 1 year ) . 4 . Severe restrictive lung disease : force vital capacity ( FVC ) &lt; 50 % predict , FVC &lt; 1.2 liter . 5 . Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % predict . 6 . Residual volume ≥ 120 % predict . 7 . Obstructive lung disease : forced expiratory volume 1 second ( FEV1 ) /FVC ) &lt; 0.70 . 8 . Documented sustained improvement patient 's IPF condition 12 month prior randomization without IPFspecific therapy . 9 . Recent pulmonary upper respiratory tract infection ( 4 week prior randomization ) . 10 . Acute chronic impairment ( dyspnea ) limit ability comply study requirement ( e.g. , pulmonary function test ) . 11 . Chronic heart failure New York Heart Association class III/IV know leave ventricular ejection fraction &lt; 25 % . 12 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. 13 . Estimated creatinine clearance &lt; 30 mL/min . 14 . Aspartate aminotransferase ( AST ) and/or alanine aminotransferase &gt; 1.5 x upper limit normal . 15 . Hemoglobin &lt; 75 % low limit normal range . 16 . Systolic blood pressure &lt; 100 mmHg . 17 . Pregnant breastfeeding . 18 . Current drug alcohol dependence . 19 . Chronic treatment follow drug ( within 4 week randomization ) : Oral corticosteroid ( &gt; 20 mg/day prednisone equivalent ) , Immunosuppressive cytotoxic drug include cyclophosphamide azathioprine , Antifibrotic drug include pirfenidone , D penicillamine , colchicine , tumor necrosis factor α blocker , imatinib interferon γ , Chronic use Nacetylcysteine prescribe IPF ( &gt; 600 mg/day ) . Oral anticoagulant prescribe IPF . 20 . Treatment endothelin receptor antagonist within 4 week prior randomization . 21 . Systemic treatment within 4 week prior randomization cyclosporine A tacrolimus , everolimus , sirolimus ( calcineurin mammalian target rapamycin ( mTOR ) inhibitor ) . 22 . Treatment Cytochrome P450 3A inducer within 4 week prior randomization . 23 . Known hypersensitivity drug class study drug , excipients . 24 . Planned treatment , treatment another investigational drug within 4 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>MUSIC</keyword>
</DOC>